Anti-Obesity Therapeutics Market - Global Forecast 2026-2032

The anti-obesity therapeutics market is evolving rapidly, shaped by clinical advances, shifting payer dynamics, and rising patient expectations. Senior decision-makers must understand how these forces are impacting product innovation, access, and commercial strategies today and in the years ahead.

Market Snapshot

The Anti-Obesity Therapeutics Market grew from USD 11.69 billion in 2025 to USD 12.67 billion in 2026. It is expected to continue growing at a CAGR of 8.87%, reaching USD 21.21 billion by 2032.

Scope & Segmentation

This report provides a strategic breakdown of the anti-obesity therapeutics ecosystem, empowering executives to make data-driven decisions across the global landscape. Key areas of focus include:

Treatment Types: Both pharmacologic agents (such as bupropion-naltrexone, liraglutide, orlistat, phentermine-topiramate, semaglutide, and tirzepatide) and procedural options (including adjustable gastric banding, endoscopic sleeve gastroplasty, and gastric bypass surgery) are analyzed, each presenting distinct clinical and access considerations.
Drug Types: The segmentation covers prescription-only versus over-the-counter therapies, directly influencing marketing, distribution, and patient support structures.
Routes of Administration: Oral (capsules, tablets) and parenteral (intravenous, subcutaneous) approaches are examined with attention to their operational impact on patient adherence and provider workflows.
Formulations: Liquid, semi-solid, and solid forms are assessed for their implications on stability, delivery logistics, and manufacturing complexity.
Distribution Channels: Hospital and clinic pharmacies, online channels, and retail settings are outlined for their role in procurement and patient access.
Geographic Regions: Strategic analysis covers the Americas, Europe, Middle East & Africa, and Asia-Pacific, with focus on regional regulatory frameworks, access dynamics, and commercial pathways.
Technology and Partnerships: The report details advances in pharmacological innovation, adoption of digital therapeutics, and new biopharma-technology alliances supporting integrated care models.

Key Takeaways

Clinical breakthroughs are prompting a reassessment of treatment paradigms, with emerging combinations and earlier intervention pathways gaining traction.
Payers are calling for outcomes-based contracts and demonstrated value, leading to new approaches in evidence generation and market access.
The maturation of digital support systems is enabling scalable patient engagement models that address adherence and persistence in chronic disease management.
Supply chain strategies are adapting to support parenteral medications and reduce single-source and trade exposure, driving investment in diversified logistics and manufacturing readiness.
Industry partnerships between biopharma and technology providers deliver a competitive edge by integrating pharmacotherapy with real-time patient monitoring and support.
Regional and national differences in regulatory approval, reimbursement structures, and patient preferences require locally tailored commercialization approaches.

Tariff Impact

Recent trade policy changes have added complexity to supply chains and procurement for anti-obesity therapeutics. Manufacturers are mitigating tariff-related risks by diversifying suppliers, nearshoring production, and reassessing logistics to maintain consistent delivery. Procurement contracts increasingly feature risk-adjusted clauses and thorough supply chain mapping, while clinical formulary committees are integrating supply reliability and procurement risk into decision frameworks.

Methodology & Data Sources

Our analysis synthesizes peer-reviewed clinical studies, regulatory filings, trial registries, public industry disclosures, and in-depth interviews with market stakeholders. Primary evidence is triangulated with manufacturing and logistics intelligence. Every conclusion is underpinned by rigorous source validation and scenario analysis for transparency and actionable insights.

Why This Report Matters

Enables leaders to align commercial, medical, and operational strategy to fast-changing clinical and policy trends.
Supports risk-adjusted planning by providing critical insights on supply chain, payer partnerships, and regional market access.
Offers a proven framework for launching and scaling differentiated therapeutic solutions in a fragmented and competitive market.

Conclusion

As the anti-obesity therapeutics market transforms, adapting to evolving evidence, payer requirements, and patient needs is essential for sustainable growth. Strategic, coordinated action across evidence generation, manufacturing resilience, and patient engagement will separate market leaders from the rest.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Therapeutics Market, by Treatment Type

8.1. Medications
8.1.1. Bupropion-Naltrexone
8.1.2. Liraglutide
8.1.3. Orlistat
8.1.4. Phentermine-Topiramate
8.1.5. Semaglutide
8.1.6. Tilzepatide
8.2. Treatments
8.2.1. Adjustable Gastric Banding
8.2.2. Endoscopic Sleeve Gastroplasty
8.2.3. Gastric Bypass Surgery

9. Anti-Obesity Therapeutics Market, by Drug Type

9.1. Over-The-Counter Drugs
9.2. Prescription Drugs

10. Anti-Obesity Therapeutics Market, by Route Of Administration

10.1. Oral Administration
10.1.1. Capsules
10.1.2. Tablets
10.2. Parenteral Administration
10.2.1. Intravenous
10.2.2. Subcutaneous

11. Anti-Obesity Therapeutics Market, by Drug Formulation

11.1. Liquid Dosage Forms
11.2. Semi-Solid Dosage Forms
11.3. Solid Dosage Forms

12. Anti-Obesity Therapeutics Market, by Distribution Channel

12.1. Hospitals & Clinics Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies

13. Anti-Obesity Therapeutics Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Anti-Obesity Therapeutics Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Anti-Obesity Therapeutics Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Anti-Obesity Therapeutics Market
17. China Anti-Obesity Therapeutics Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Alizyme PLC
18.6. Amgen Inc.
18.7. Arena Pharmaceuticals Inc.
18.8. Boehringer Ingelheim International GmbH
18.9. Bristol-Myers Squibb Company
18.10. Currax Pharmaceuticals LLC
18.11. Eisai Co. Ltd.
18.12. Eli Lilly and Company
18.13. F. Hoffmann-La Roche Ltd
18.14. FlaxoSithKline plc.
18.15. GlaxoSmithKline PLC
18.16. Johnson & Johnson Services Inc.
18.17. Merck & Co. Inc.
18.18. Nalpropion Pharmaceuticals Inc.
18.19. Norgine B.V.
18.20. Novartis AG
18.21. Novo Nordisk A/S
18.22. Orexigen Therapeutics Inc.
18.23. Pfizer Inc.
18.24. Rhythm Pharmaceuticals, Inc.
18.25. Sanofi S.A.
18.26. SHIONOGI & Co., Ltd.
18.27. Takeda Pharmaceutical Company Limited
18.28. Vivus Inc.
18.29. Zydus Lifesciences Limited

List of Figures

FIGURE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 91. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 92. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 101. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 102. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 103. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 104. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 111. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 112. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 127. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 128. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 130. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 131. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 132. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 133. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 136. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 141. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 142. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 144. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 146. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 149. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 150. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 151. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 152. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 153. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 154. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 156. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 168. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 170. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 171. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 172. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 173. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 174. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 176. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 177. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 178. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 180. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 181. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 182. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 183. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 186. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 187. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 192. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 193. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 194. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 196. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 198. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 199. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 200. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 201. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 202. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 203. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 204. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 206. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 207. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 210. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 211. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 212. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 213. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 214. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 216. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 217. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 218. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 219. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 220. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 221. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 222. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 223. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 224. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 227. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 228. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 233. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 234. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 236. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 238. UNITED STATES ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 240. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 241. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
TABLE 242. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2032 (USD MILLION)
TABLE 243. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 244. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 245. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 246. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2032 (USD MILLION)
TABLE 248. CHINA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Anti-Obesity Therapeutics market report include:

Alizyme PLC
Amgen Inc.
Arena Pharmaceuticals Inc.
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Currax Pharmaceuticals LLC
Eisai Co. Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
FlaxoSithKline plc.
GlaxoSmithKline PLC
Johnson & Johnson Services Inc.
Merck & Co. Inc.
Nalpropion Pharmaceuticals Inc.
Norgine B.V.
Novartis AG
Novo Nordisk A/S
Orexigen Therapeutics Inc.
Pfizer Inc.
Rhythm Pharmaceuticals, Inc.
Sanofi S.A.
SHIONOGI & Co., Ltd.
Takeda Pharmaceutical Company Limited
Vivus Inc.
Zydus Lifesciences Limited

Table Information

Report Attribute	Details
No. of Pages	193
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 12.67 Billion
Forecasted Market Value ( USD ) by 2032	$ 21.21 Billion
Compound Annual Growth Rate	8.8%
Regions Covered	Global
No. of Companies Mentioned	26

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot

Scope & Segmentation

Key Takeaways

Tariff Impact

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Anti-obesity Prescription Drugs Market - Global Forecast 2026-2032

Obesity Market Report and Forecast 2025-2034

Obesity Treatment Market - Global Forecast 2026-2032

Obesity: 68-Market Analysis and Sales Forecast

Digital Health for Obesity - Global Strategic Business Report